Hemi-Ablative Low-Dose-Rate Prostate Brachytherapy for Unilateral Localised Prostate Cancer.
To report clinical outcomes of the Hemi-Ablative Prostate Brachytherapy (HAPpy) trial evaluating treatment-related toxicity and effectiveness of hemi-gland (HG) low-dose-rate (LDR) brachytherapy as a focal approach to control unilateral localised prostate cancer. Single institution phase IIS pilot study of patients treated with 4D Focal Brachytherapy. The primary outcome was patient-reported toxicity 24 months post-implant. Secondary outcome was assessment of disease control. Outcomes in HG were compared to WG controls obtained from our prospective cohort registry by negative binomial (NB) and linear regression models. Pre-treatment demography was similar between the 30 HG cases and 362 WG controls. Post-implant dosimetry was similar for the prostate gland target volumes and significantly reduced for the urethra and bowel in HG relative to WG controls, but this did not translate into a difference in post-implant mean symptom scores between the two groups. Nevertheless, the change in score from baseline indicated that the impact on pre-treatment symptom status was less after HG implants. Only HG patients showed a return to baseline urinary scores as early as 12 months. Sexual potency was conserved in 73% and 67% of HG and WG patients respectively (p=0.84). Post-implant PSA kinetics revealed that baseline PSA was reduced at 24 months by 78% and 88% in HG and WG respectively (p<0.05). Treatment relapse occurred in 1 (3%) HG patient 55 months post-implant and in 9 (3%) WG cases 32 to 67 months post-implant. This pilot study suggests that treatment-related toxicity and biochemical outcomes after HG implants are broadly similar to those observed with WG treatment despite the lower dose delivered by HG implants.